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 Introduction 
 The mortality rate among patients with 
bacterial meningitis and the frequency of 
neurological sequelae among those who 
 survive are high, despite major progress in 
intensive care and effective antimicrobial che-
motherapy  (1,2) . Case fatality rates and risk of 
sequelae following meningitis are reported to 
be higher for  Streptococcus pneumoniae than 
 Neisseria meningitidis or  Hemophilus influenzae 
 (3,4) . Furthermore, following the introduction 
of  Hemophilus type b vaccine,  S. pneumoniae 
has become the most common cause of the 
disease  (5) . The ability of  S. pneumoniae to 
 alter the host inflammatory response  (6) 
 accounts for the high level of neurological 
(74.7%) and systemic complications (37.9%) 
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observed  (7) . Neurological complications in-
clude seizure (27.6%), diffuse brain swelling 
(28.7%), hydrocephalus (16.1%) hearing loss 
(19.7%), and ischemic or hemorrhagic brain 
damage (21.8%)  (7) . In a recent retrospective 
study, Kastenbauer et al. showed that 67% of 
ischemic injuries were caused by identified 
arteritis  (7) . This dramatic complication is re-
lated to a complex proinflammatory cascade 
initiated by the release of bacterial wall com-
ponents, pneumolysin, cell surface proteins 
and free radicals  (6) . Following pneumococ-
cal autolysis a rapid increase of proinflamma-
tory cytokines (interleukin [IL]-1  , tumor 
necrosis factor [TNF]-, IL-6) and chemokines 
(IL-8, macrophage inflammatory protein 
[MIP] 1-2) is observed in cerebrospinal fluid 
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(CSF) and leads to the blood – brain barrier (BBB) disruption  (8) . 
Over the past few years, experimental studies provided  some 
evidence for a central role of matrix metalloproteinases 
(MMPs) in bacterial meningitis  (6,9 – 14) . MMPs are zinc-
 dependent endopeptidases that can degrade all components 
of the extracellular matrix. MMPs are expressed as zymogens 
by brain-resident cells  (15 – 17) and leukocytes  (18) . The extra-
cellular processing of the zymogen generates the active form 
of the enzyme. In experimental meningitis, MMPs contribute 
to BBB disruption, neuronal injury, and leukocyte recruitment 
across the endothelium into the CSF  (14,19 – 21) . Despite our 
increasing understanding of the pathophysiological cascades 
involved in bacterial meningitis, to date only dexamethasone 
has demonstrated its clinical efficacy as adjunctive therapy 
 (3,22,23) . Dexamethasone decreases the rate of hearing loss 
and mortality  (3,23) . However, the actual impact of corticoste-
roids on delayed vascular complications and secondary isch-
emic brain injury is unknown. 
 We report a case of cerebral vasculitis following acute pneu-
mococcal meningitis responding to delayed corticosteroid 
treatment, later associated with cyclophosphamid. Serial CSF 
examinations showed a time relationship between MMP-9 
 levels and the vasculitic process, but no relation with CSF 
cellularity. 
 Case Report 
 A 53-year-old healthy African male presented with a 2-day 
 history of fever and back pain. He was admitted to a local 
hospital for confusion and stupor. A lumbar puncture showed 
purulent CSF with Gram-positive cocci. Therapy with cipro-
floxacin, ceftriaxone and co-trimoxazole was initiated. The 
following day, the patient developed a left-side hemiplegia, 
 Fig. 1.  Axial diffusion-weighted MRI shows multiple lesions in the superior part of the frontal and parietal lobes  (A) in the midbrain  (B) 
and in the basal ganglion areas  (C) . After reduction of prednisone, repeated MRI revealed new right fronto-parasagital lesions  (D) , left 
temporo-occipital  (E) , and occipital areas (F). Angio-MRI revealed vessel-wall irregularities (arrows), focal dilatation, and narrowing, 
mostly in the middle and posterior cerebral arteries  (G) . 
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was unresponsive and only capable of eye pursuit. Brain 
computed tomography (CT) showed bifrontal hypodensities. 
Six days after  admission to the local hospital, the patient was 
transferred to our ICU. A second brain CT scan performed on 
admission confirmed bifrontal lesions and new hypodensities 
in the right posterior arm of the internal capsula. The lumbar 
 puncture showed a white blood cell count of 300/mm 3 with 
84% neutrophils, 14% lymphocytes, 2% monocytes, 3.9 mmol/L 
glucose, 2.53 g/L proteins, but cultures remained sterile and a 
polymerase chain reaction confirmed the pneumococcal 
 infection. Antimicrobial chemotherapy was modified to treat 
potentially resistant pneumococci (vancomycin associated 
with rifampicin). On day 4 in the ICU, the patient developed 
a right hemiplegia, associated with a complete loss of contact. 
Magnetic resonance imaging (MRI) showed numerous small 
lesions in the white matter and the basal ganglia ( Figure 1A ). 
Angiography showed pathological changes (vessel wall ir-
regularities, focal dilatation and narrowing) of most cerebral 
arteries, particularly evident in the medial and posterior cere-
bral arteries, highly evocative of cerebral arteritis ( Figure 1B ). 
A new  lumbar puncture showed 57/mm 3 white blood cell 
count, with 65% neutrophils, 30% lymphocytes, 5% mono-
cytes, 5.1 mmol/L glucose, 2.65 g/L proteins, and no bacteria. 
The unfavorable evolution motivated the initiation of steroids 
as  adjunctive therapy. Methylprednisolone, 500 mg daily, sta-
bilized the patient’s clinical condition with no new lesion on 
MRI. After 5 days, methylprednisolone was replaced by 
 prednisone 1 mg/kg followed by 0.25 mg/kg/day. On day 7, 
after reduction of prednisone to 0.25 mg/kg/day, the patient’s 
clinical status deteriorated. His level of consciousness dropped 
and only stereotyped movements were elicited by painful 
stimulation. MRI showed new lesions in the left occipital area 
( Figure 1C ) and a progression of the vasculitic process on the 
posterior branch of both middle cerebral artery branches. 
High doses of steroids were reintroduced (methylpred-
nisolone 1 g iv per day, for 5 days) and later associated with 
cyclophosphamid (1 g iv). Following the optimization of 
 immunosuppressive therapy, the patient improved progres-
sively. After 1.5 months of evolution, he was capable of 
 directed movements of the right arm and left leg and a visual 
contact was again possible. 
 Gelatinase levels in our patient’s CSF were investigated on 
days 0, 4, and 19 of hospitalization in the ICU. MMP measure-
ments were performed using a classical zymographic method 
described elsewhere  (18,24) . Briefly, CSF samples were loaded 
into 10% Tris sodium dodecyl sulfate (SDS) polyacrylamide 
gels containing gelatin (EC61755box, Invitrogen, Carlsbad, 
CA). After electrophoresis, gels were washed in 2.5% Triton 
X-100 for 30 minutes, rinsed and  incubated in 50 mM Tris, 0.2 
 M NaCl, 5 m M CaCl 2 , buffer overnight at 37°C. Gels were 
stained with 0.2% Coomassie brilliant blue R-250 (Bio-Rad 
161-0400, Hercules, CA), 10% acetic acid, 30% methanol and 
destained in 10% acetic acid, 30% methanol. White bands on a 
blue background indicated zones of digestion corresponding 
to the presence of different MMPs, identified on the basis of 
their molecular weight.  Serial dilutions of pro-MMP-9 and -2 
standards (Calbiochem-Novabiochem, La Jolla, CA) were 
used to draw a standard curve. Bands were scanned using a 
densitometer and quantifications were performed using the 
National Institutes of Health 1.63 image software. 
 Although control CSF (obtained from patients investi-
gated for noninflammatory neurological disease) did not 
show any pro-MMP-9 but only pro-MMP-2 (0.54  µ g/mL), the 
first CSF obtained from the patient at the time of ICU admis-
sion showed a dramatic increase of pro-MMP9, 0.11  µ g/mL 
 ( Figure 2 ). The second CSF examination, at the time of the 
patient’s neurological deterioration, showed increasing  levels 
of pro-MMP-9 (0.13  µ g/mL) and pro-MMP-2 (0.74  µ g/mL). 
After several days of corticotherapy, a significant decrease of 
pro-MMP-9 (0.09  µ g/mL) and pro-MMP-2 (0.5  µ g/mL) CSF 
levels were observed. The active form of MMP-9 was also 
 detected and decreased with corticotherapy. Whereas the 
number of neutrophils decreased dramatically between the 
first and second fluid examination, the level of MMPs 
 increased. In accordance with CSF levels, blood levels of 
MMP-9 and -2 dramatically decreased after the introduction 
of steroids ( Figure 2 ). 
 Comment 
 This case report illustrates that central nervous system 
(CNS) vascular inflammation is a key issue in pneumococcal 
meningitis. Although  bacteria are responsible for triggering 
host inflammatory  response, the latter may last and perpetu-
ate despite correct antimicrobial therapy and early bacterial 
disappearance from CNS. Our observation showed that CSF 
and blood levels of MMP-9 and -2 paralleled the patient’s vas-
cular complications and clinical evolution. Corticotherapy 
 Fig. 2.  Zymographic analysis of gelatinase levels in blood and CSF 
samples obtained from the patient at his admission. Pro-MMP-9 
is not detectable, whereas pro-MMP-2 is constitutively produced in 
the CSF obtained from patients with noninflammatory neurological 
disease (a representative sample is shown, normal control). High 
CSF and blood levels of the proform of MMP-9 and MMP-2 and of 
the active form of MMP-9 are observed in the meningitic patient, 
at the admission in the ICU. Increasing CSF levels of both gelatinases 
are detected at the time of ischemic complications. Decreased but 
persisting levels of pro-MMP-9 are osbserved during corticosteroid 
treatment. 
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initiation stabilized the patient’s clinical condition and was 
associated with a reduction in MMP-9 and -2 levels. The re-
duction of steroids was followed by a rapid clinical deteriora-
tion caused by vasculitis relapse, suggesting some efficacy of 
the treatment. According to one meta-analysis (23) and recent 
randomized study  (3) , corticosteroid treatment is efficient and 
indicated only very early in the course of bacterial meningitis, 
prior or at the time of the first dose of antibiotics. No scientific 
evidence supports delayed or prolonged (> 4 days) treatment 
in pneumococcal meningitis. Our report suggests that immu-
nosuppressive therapy could be beneficial for delayed com-
plications related to vascular inflammation. It also suggests 
that MMPs, in particular MMP-9, could be a potential target 
of new adjunctive therapies. However, our isolated observa-
tion needs confirmation in a large prospective study. Recently, 
Leib et al. showed that the association of a broad-spectrum 
inhibitor of MMPs to antibiotics reduced neuronal necrosis 
and apoptosis in a model of experimental meningitis  (13,14) . 
These results were challenged by Bottcher et al., who showed 
that MMP-9- deficient mice infected with  S. pneumoniae were 
not protected as compared with wild-type animals. Neverthe-
less, there is growing experimental evidence that the neuro-
logical sequelae observed in bacterial meningitis  (25,26) are 
related to the inappropriate inflammatory host response. Our 
report shows that, at the time of neurological complications, 
although no bacteria and only a few inflammatory cells were 
detected in the patient’s CSF, CSF and blood levels of MMP-9 
were elevated. This suggests that MMPs might be actively in-
volved in the vasculitic process or be a potential marker of 
this vascular complication. If this is the case, MMP-9 detec-
tion could help to identify patients susceptible to benefit from 
aggressive and prolonged immunosuppression. 
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